Andrew Udell, a sales and marketing veteran, has been appointed head of commercial operations in North America for Sweden’s Calliditas Therapeutics AB. This coincides with the start of a Phase 3 trial of a product for IgA nephropathy, where Calliditas is targeting the US market.
Mr Udell previously led commercial operations at the Israeli company Neuroderm Ltd and before that, headed marketing and communications at Intrexon Corp. He holds a BSc from Lehigh University and an MBA from the University of Connecticut, both in the US.
Calliditas announced the appointment on 8 January 2019.
Copyright 2019 Evernow Publishing Ltd